Immunomodulatory Agents (IMiDs)
Thalidomide (Thalomid®)
Classes of Myeloma Drugs
Proteasome Inhibitors (PI's)
Bortezomib (Velcade®)
Monoclonal Antibodies (MoAbs)
Daratumumab (Darzalex® and Darzalex Faspro® )
Target: CD38
Lenalidomide (Revlimid®)
Carfilzomib (Kyprolis®)
Elotuzumab (Empliciti®)
Target: SLAM F7
Pomalidomide (Pomalyst®)
Ixazomib (Ninlaro®)
Isatuximab (Sarclisa® )
Target: CD38
Cytotoxic/ Steroids
XPO1 Inhibitors Antibody Drug Conjugate (ADC)
Melphalan (Alkeran®)
Selinexor (Xpovio®)
MOA: XPO1 Inhibitor Belantamab mafodotin (Blenrep®)*
Target: BCMA
Cyclophosphamide (Cytoxan®)
Bendamustine (Treanda®)
Steroids: Dexamethasone (Decadron®) Prednisone (Deltasone®)
Other CAR (Chimeric Antigen Receptor) T-Cell Therapy
Venetoclax (Venclexta®)* for t(11;14)
Idecaptagene vicleucel (ABECMA®)
Target: BCMA
Ciltacaptagene autoleucel (CARVYKTI™ )
Target: BCMA
MOA = Mechanism of Action
* Approval pending in myeloma
This is not to meant to be an exhaustive list but a guide to key therapies.
Bispecific Antibodies (BiSAb)
Teclistamab (TECVAYLI®)
Target: BCMA
Talquetamab (TALVEYTM)
Target: GPRC5D
Elranatamab (ELREXFIOTM)
Target: BCMA
Cevostamab*
Target: FcRH5
Supportive Care
Bone strengthener: Pamidronate (Aredia®)
Zoledronate (Zometa®)
Denosumab (Xgeva®)
Infection Prevention: Acyclovir, Valacyclovir; Levofloxacin, SMX-TMP; IVIG
SMX-TMP = sulfamethoxazole-trimethoprim
IVIG = intravenous immunoglobulin